Eledon Pharmaceuticals, Inc. (ELDN) stock
ELDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.12−0.25 (-10.57%)
Close on Nov 13, 2026Market cap $171.87MP/E –Yield –
Eledon Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Eledon Pharmaceuticals's total assets was $106.64M at Sep 30, 2026. For fiscal 2025 it was $169.01M, down 4.7% from the year before. Over ten years it grew 9.5% a year on average. The highest annual figure on record is $197.19M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $169.01M | -4.7% |
| FY2024 | Dec 31, 2024 | $177.41M | +99.2% |
| FY2023 | Dec 31, 2023 | $89.07M | -4.0% |
| FY2022 | Dec 31, 2022 | $92.79M | -45.6% |
| FY2021 | Dec 31, 2021 | $170.55M | -13.5% |
| FY2020 | Dec 31, 2020 | $197.19M | +1703.9% |
| FY2019 | Dec 31, 2019 | $10.93M | -35.8% |
| FY2018 | Dec 31, 2018 | $17.03M | -18.5% |
| FY2017 | Dec 31, 2017 | $20.89M | +1646.8% |
| FY2016 | Dec 31, 2016 | $1.20M | -98.2% |
| FY2015 | Dec 31, 2015 | $67.97M | -36.9% |
| FY2014 | Dec 31, 2014 | $107.74M | +233.7% |
| FY2013 | Dec 31, 2013 | $32.29M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $106.64M | -17.9% |
| Q2 FY2026 | Jun 30, 2026 | $126.09M | -13.0% |
| Q1 FY2026 | Mar 31, 2026 | $146.67M | -9.1% |
| Q4 FY2025 | Dec 31, 2025 | $169.01M | -4.7% |
| Q3 FY2025 | Sep 30, 2025 | $129.86M | +13.3% |
| Q2 FY2025 | Jun 30, 2025 | $144.91M | +20.3% |
| Q1 FY2025 | Mar 31, 2025 | $161.31M | +99.6% |
| Q4 FY2024 | Dec 31, 2024 | $177.41M | +99.2% |
| Q3 FY2024 | Sep 30, 2024 | $114.58M | +19.3% |
| Q2 FY2024 | Jun 30, 2024 | $120.48M | +12.8% |
| Q1 FY2024 | Mar 31, 2024 | $80.82M | -1.8% |
| Q4 FY2023 | Dec 31, 2023 | $89.07M | -4.0% |
| Q3 FY2023 | Sep 30, 2023 | $96.07M | -35.8% |
| Q2 FY2023 | Jun 30, 2023 | $106.79M | -31.0% |
| Q1 FY2023 | Mar 31, 2023 | $82.31M | -49.0% |
| Q4 FY2022 | Dec 31, 2022 | $92.79M | -45.6% |
| Q3 FY2022 | Sep 30, 2022 | $149.59M | -15.6% |
| Q2 FY2022 | Jun 30, 2022 | $154.71M | -16.1% |
| Q1 FY2022 | Mar 31, 2022 | $161.38M | -15.8% |
| Q4 FY2021 | Dec 31, 2021 | $170.55M | -13.5% |
| Q3 FY2021 | Sep 30, 2021 | $177.17M | -8.0% |
| Q2 FY2021 | Jun 30, 2021 | $184.31M | +1655.1% |
| Q1 FY2021 | Mar 31, 2021 | $191.68M | +1297.1% |
| Q4 FY2020 | Dec 31, 2020 | $197.19M | +1703.9% |
| Q3 FY2020 | Sep 30, 2020 | $192.59M | +1165.5% |
| Q2 FY2020 | Jun 30, 2020 | $10.50M | -42.4% |
| Q1 FY2020 | Mar 31, 2020 | $13.72M | +2.0% |
| Q4 FY2019 | Dec 31, 2019 | $10.93M | -35.8% |
| Q3 FY2019 | Sep 30, 2019 | $15.22M | -23.6% |
| Q2 FY2019 | Jun 30, 2019 | $18.22M | -20.7% |
| Q1 FY2019 | Mar 31, 2019 | $13.45M | -48.1% |
| Q4 FY2018 | Dec 31, 2018 | $17.03M | -18.5% |
| Q3 FY2018 | Sep 30, 2018 | $19.93M | -13.4% |
| Q2 FY2018 | Jun 30, 2018 | $22.97M | -14.5% |
| Q1 FY2018 | Mar 31, 2018 | $25.92M | +0.3% |
| Q4 FY2017 | Dec 31, 2017 | $20.89M | +1646.8% |
| Q3 FY2017 | Sep 30, 2017 | $23.02M | – |
| Q2 FY2017 | Jun 30, 2017 | $26.84M | – |
| Q1 FY2017 | Mar 31, 2017 | $25.83M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.20M | – |
See a number that looks wrong?